A comprehensive approach to pain management for patients with degenerative joint disease

Authors

  • Galyna Protsenko SI «NSC «Institute of Cardiology named after Academician M. D. Strazheskо» NAMS of Ukraine», Kyiv, Ukraine
  • Ivanova Kateryna SI «NSC «Institute of Cardiology named after Academician M. D. Strazheskо» NAMS of Ukraine», Kyiv, Ukraine

DOI:

https://doi.org/10.15674/0030-59872020133-39

Keywords:

degenerative joint diseases, anesthesia, nabumeton, chondroprotectors

Abstract

Osteoarthritis is a chronic degenerative-inflammatory joint disease, which is characterized by cartilage damage, bone epiphyses remodeling, osteophyte appearence, and persistent joint deformity. OA impairs the synthesis of proteoglycans by chondrocytes, increases the activity of proinflammatory cytokines (interleukin-1β, -4, -6, -17, -18, tumor necrosis factor-α), immunological changes occur by increasing the function of T-helper cells and the appearance of autoantibodies to cartilage components, activation of lipid peroxidation and reduction of antioxidant protection system. Osteoarthritis treatment is aimed to reducing pain, inflammation and slowing the degenerative changes in cartilage. Non-steroidal anti-inflammatory drugs (NSAIDs) to which Nabumeton («Synmethon») refers are prescribed as symptomatic drugs. It is a moderately specific inhibitor of COX-2, a characteristic feature of which is the lack of effect on the gastric mucosa due to its weak alkaline properties. It does not alter the pharmacokinetics of antacids, and conversely, aluminum-containing antacids do not have a significant effect on the bioavailability of naumetone. It differs from other acidic NSAIDs. The drug is recommended for long-term use in patients with Osteoarthritis with synovitis. Chondroprotectors, which modify the structure of cartilage, are assigned in parallel. Among them, the highest level of evidence is glucosamine sulfate and chondroitin sulfate. Chondroitin is a gel-forming polysaccharide with high hydrophilicity. Its hydrocolloid properties are responsible for protecting the cartilage during the loads. Glucosamine is a building material for glucosaminoglycans that form the cartilage structure. Combination medicines are increasingly being used for initial treatment — the «Protecon Fast®» NSAID with chondroprotectants and the «Protekon®» (glucosamine sulfate, chondroitin sulfate) by «Organosin Limited», manufactured by «Evertogen Life Sciences Limited». Taking one drug instead of several improves patient compliance and is pharmacologically sound.

Author Biographies

Galyna Protsenko, SI «NSC «Institute of Cardiology named after Academician M. D. Strazheskо» NAMS of Ukraine», Kyiv

MD, Prof. of the Department of Non-Coronary Heart Diseases, Rheumatology and Therapy

Ivanova Kateryna, SI «NSC «Institute of Cardiology named after Academician M. D. Strazheskо» NAMS of Ukraine», Kyiv

PhD of the Department of Non-Coronary Heart Diseases, Rheumatology and Therapy

References

  1. Alyoshina, A., & Kolos, M. (2015). Correction of functional disorders of the musculoskeletal system of students in the process of physical education. Physical education, sport and health culture in modern society, 4(32), 52-56. [in Ukrainian]
  2. Sushko, R. O., & Doroshenko, E. Yu. (2015). Technical and tactical actions of highly qualified basketball players at the stage of maximum realization of individual capabilities. Scientific Journal, 9, 72-76. [in Ukrainian]
  3. Korolkov, O., Bolkhovitin, P., Korolkova, A., & Nasr Al Kali. (2017). Results of application of the method of continuous passive movement in the process of physical rehabilitation of patients with pathology of the knee joint. Slobozhansky Scientific and Sports Bulletin, 4(60), 68-72. DOI: 10.15391/ snsv.2017-4.012. [in Ukrainian]
  4. Kovalchuk, O., & Kozin, M. (2018). Peculiarities of physical rehabilitation in patients with lumbar osteochondrosis. Pereyaslav-Khmelnytsky. [in Ukrainian]
  5. Naumenko, L. Yu., Ipatov, A. V., Zub, T. O., & Mamatiev, A. O. (2018). The state of disability due to injuries of the upper extremity in Ukraine in 2017. Trauma, 19(4), 9-14. DOI: 10.22141/1608-1706.4.19.2018.142100. [in Ukrainian]
  6. Balabanova, R. M. (2013). A new approach to the treatment of osteoarthritis as a chronic inflammatory disease. Modern rheumatology, 2, 95-98. [in Russian]
  7. Shostak, N. A., & Pravdyuk, N. A. (2016). Osteoarthritis: determinants of pain, approaches to treatment. Rheumatology, 22, 1476-1480. [in Russian]
  8. Zabello, T. V., Miromanov, A. M., & Miromanova, N. A. (2015). Genetic aspects of the development of osteoarthritis. Fundamental research, 1–9, 1970-1976. [in Russian]
  9. Chepeleva, M. V., Chegurov, O. K., Kuznetsova, E. I., & Shved, N. S. (2014). Immunity indices in patients with aseptic instability of the knee joint. Clinical laboratory diagnostics, 8, 18-21. [in Russian]
  10. Larsson, S., Englund, M., Struglics, A., & Lohmander, L. (2015). Interleukin-6 and tumor necrosis factor Alpha in synovial fluid are associated with progression of radiographic knee osteoarthritis in subjects with previous meniscectomy. Osteoarthritis and Cartilage, 23(11), 1906-1914. https://doi.org/10.1016/j.joca.2015.05.035
  11. Jordan, K. M. (2003). EULAR recommendations 2003: An evidence based approach to the management of knee osteoarthritis: Report of a task force of the standing committee for international clinical studies including therapeutic trials (ESCISIT). Annals of the Rheumatic Diseases, 62(12), 1145-1155. https://doi.org/10.1136/ard.2003.011742
  12. Zupanets, I. A., & Andreeva, E. A. (2005). To the characteristic of the gastrotoxic action of non-steroidal anti-inflammatory drugs - nonselective, selective and specific inhibitors of COX-2 (experimental study). Modern gastroenterology, 2, 39-43. [in Russian]
  13. Nasonov, E. L., & Karateev, A. E. (2000). Gastric lesions associated with the use of non-steroidal anti-inflammatory drugs. Clinical medicine, 78(3), 4-10. [in Russian]
  14. Fries, J. F., Murtagh, K. N., Bennett, M., Zatarain, E., Lingala, B., & Bruce, B. (2004). The rise and decline of nonsteroidal antiinflammatory drug-associated gastropathy in rheumatoid arthritis. Arthritis & Rheumatism, 50(8), 2433-2440. https://doi.org/10.1002/art.20440
  15. Hochberg, M. C., Altman, R. D., April, K. T., Benkhalti, M., Guyatt, G., McGowan, J., … & Tugwell, P. (2012). American College of rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care & Research, 64(4), 465-474. https://doi.org/10.1002/acr.21596
  16. Bottegoni, C., Muzzarelli, R. A., Giovannini, F., Busilacchi, A., & Gigante, A. (2014). Oral chondroprotection with nutraceuticals made of chondroitin sulphate plus glucosamine sulphate in osteoarthritis. Carbohydrate Polymers, 109, 126-138. https://doi.org/10.1016/j.carbpol.2014.03.033
  17. Singh, J. A., Noorbaloochi, S., MacDonald, R., & Maxwell, L. J. (2015). Chondroitin for osteoarthritis. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd005614.pub2
  18. Potebnya, G. P., & Chornyi, V. S. (2016). The role of chondroprotectors in the management of the clinical course of osteoarthritis: realities and prospects. Practitioner, 1, 34-37. [in Ukrainian]
  19. Davies, N. M., & Anderson, K. E. (1997). Clinical pharmacokinetics of Diclofenac. Clinical Pharmacokinetics, 33(3), 184-213. https://doi.org/10.2165/00003088-199733030-00003
  20. Marzo, A., Bo, L. D., & Verga, F. (2008). Pharmacokinetics of diclofenac potassium salt after oral administration of sachets and tablets. Modern rheumatology, 2(3), 59-63. [in Russian]
  21. Long, I., Rao, G. J., & Singhv, H. J. (2004). Еffect of nabumetone on the renal function in conscious and Effect of nabumetone on the renal function in conscious and anesthetized rats anesthetized rats. Indian Journal Pharmacology, 36(6), 363-368
  22. Sostres, C., Gargallo, C. J., & Lanas, A. (2013). Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage. Arthritis Research & Therapy, 15(Suppl 3), S3. https://doi.org/10.1186/ar4175
  23. Curhan, G. C., Willett, W. C., Rosner, B., & Stampfer, M. J. (2002). Frequency of analgesic use and risk of hypertension in younger women. Archives of Internal Medicine, 162(19), 2204. https://doi.org/10.1001/archinte.162.19.2204
  24. Protsenko, G. O., & Ivanova, K. A. (2011). Experience of application of sinmeton (nabumeton) in clinical practice. Trauma, 12(2). [in Ukrainian]
  25. Mahmood, Z., & McNamara, D. (2003). Gastro-oesophageal reflux disease and ulcer disease. Alimentary Pharmacology and Therapeutics, 18(s3), 31-37. https://doi.org/10.1046/j.0953-0673.2003.01725.x
  26. Long, I. B., Singh, H. J., & Rao, G. J. (2005). Comparative effects of indomethacin and Nabumetone on urine and electrolyte output in conscious rats. Journal of Pharmacological Sciences, 99(3), 272-276. https://doi.org/10.1254/jphs.fpj05008x
  27. Prieto, A., De Barrio, M., Martín, E., Fernández-Bohórquez, M., De Castro, F. J., Ruiz, F. J., … & Rubio, M. (2007). Tolerability to nabumetone and meloxicam in patients with nonsteroidal anti-inflammatory drug intolerance. Journal of Allergy and Clinical Immunology, 119(4), 960-964. https://doi.org/10.1016/j.jaci.2006.12.616
  28. Shi, W., Wang, Y. M., & Cheng, N. N. (2003). Meta-analysis on the effect and adverse reaction on patients with osteoarthritis and rheumatoid arthritis treated with nonsteroidal anti-inflammatory drugs. Zhonghua Liu Xing Bing Xue Za Zhi, 24(11), 1044-1048.
  29. Mufazalova, N. A. (2015). Nonsteroidal anti-inflammatory drugs. International Journal of Experimental Education, 8-2, 182-183. [in Russian]

Downloads

How to Cite

Protsenko, G., & Kateryna, I. (2024). A comprehensive approach to pain management for patients with degenerative joint disease. ORTHOPAEDICS TRAUMATOLOGY and PROSTHETICS, (1), 33–39. https://doi.org/10.15674/0030-59872020133-39

Issue

No. 1 (2020)

Section

ORIGINAL ARTICLES

License

Copyright (c) 2020 Galyna Protsenko, Ivanova Kateryna

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

The authors retain the right of authorship of their manuscript and pass the journal the right of the first publication of this article, which automatically become available from the date of publication under the terms of Creative Commons Attribution License, which allows others to freely distribute the published manuscript with mandatory linking to authors of the original research and the first publication of this one in this journal.

Authors have the right to enter into a separate supplemental agreement on the additional non-exclusive distribution of manuscript in the form in which it was published by the journal (i.e. to put work in electronic storage of an institution or publish as a part of the book) while maintaining the reference to the first publication of the manuscript in this journal.

The editorial policy of the journal allows authors and encourages manuscript accommodation online (i.e. in storage of an institution or on the personal websites) as before submission of the manuscript to the editorial office, and during its editorial processing because it contributes to productive scientific discussion and positively affects the efficiency and dynamics of the published manuscript citation (see The Effect of Open Access).